Get the Daily Brief
Latest Biotech News
Merck KGaA makes record-scale move into life-science tools with Bio-Techne acquisition
Merck KGaA agreed to buy Bio-Techne for about $11.3 billion in cash, marking its largest deal since the Sigma-Aldrich acquisition in 2015. The offer values Bio-Techne at $73 per share and...
Ionis monetizes Alexander disease franchise with Recordati ex-U.S. licensing
Recordati licensed Ionis’ Alexander disease therapeutic candidate in a deal that shifts regulatory and commercial responsibilities to the Italian company. The arrangement supports Ionis’ strategy...
Revolution’s second RAS blocker posts strong pancreatic cancer response signals and moves into Phase 3
Revolution Medicines reported high response activity for its second RAS inhibitor, zoldonrasib, in Phase 1/2 pancreatic ductal adenocarcinoma (PDAC) data focused on the KRAS G12D mutation. In...
Novartis pays Antares $105M to pursue undruggable oncology targets with small molecules
Novartis agreed to pay Antares Therapeutics $105 million upfront under a multi-year collaboration to discover small-molecule programs against cancer targets considered “undruggable.” The deal...
RQ Bio raises $115M Series A to advance long-acting flu prevention antibody program
RQ Bio raised an oversubscribed $115 million Series A to advance RQB01, a long-acting antibody therapy intended to prevent seasonal influenza in high-risk and immunocompromised populations. The...
Tempus and Angiosarcoma Awareness partner to expand rare-cancer multiomics dataset
Tempus AI partnered with Angiosarcoma Awareness to advance rare cancer research using the company’s computational resources and multiomic datasets. The collaboration incorporates roughly 600...
Natera integrates Prospera dd-cfDNA into Phase 3 kidney transplant rejection trial
Natera and Eledon Pharmaceuticals partnered to use Natera’s Prospera donor-derived cell-free DNA (dd-cfDNA) test as an exclusive longitudinal monitoring assay in Eledon’s Phase III kidney...
Sangamo enters Chapter 11, with Lilly and Astellas lined up to acquire key platforms and rare-disease programs
Sangamo Therapeutics filed for Chapter 11 bankruptcy protection and agreed to asset-sale agreements that would transfer major technology platforms and a subset of programs. In the filings, Eli...
FDA IND clearance enables Ascletis obesity peptide program to move toward clinic
Ascletis Pharma received FDA IND clearance for ASC-35, a once-monthly subcutaneous GLP-1/GIP dual peptide agonist targeting obesity. The clearance advances the candidate toward clinical evaluation...
Regulatory approval and label expansion for lipid-lowering therapy
Ionis Pharmaceuticals said the FDA approved a label expansion for Tryngolza (formerly known in development as an antisense drug targeting triglycerides), widening its use in patients with severely...
Oncology FDA action reshapes first-line breast cancer ADC competition
Gilead’s Trodelvy won an FDA nod as a first-line triple-negative breast cancer treatment, with a slightly broader label designed to strengthen its position against other ADCs in the same line of...
Late-stage trial win boosts a path to market for ADHD therapy
Otsuka reported its phase 3b ADHD trial met its primary endpoint, strengthening the company’s case ahead of an expected U.S. regulatory decision. The positive readout arrives shortly before a...
Phase III monitoring partnership ties dd-cfDNA testing to kidney transplant immunotherapy
Natera and Eledon Pharmaceuticals partnered to embed Natera’s Prospera donor-derived cell-free DNA assay into a planned Phase III kidney transplant trial of Eledon’s tegoprubart, an...
Venture funding for preventive flu antibodies moves RQB01 toward clinic
RQ Bio raised $115 million in an oversubscribed Series A to advance RQB01, a single-dose antibody therapy designed for broad, season-long prevention of seasonal influenza. The London-based biotech...
New funding for decentralized molecular diagnostics targeting HPV
Intu Diagnostics raised €1.1 million in bridge funding as it develops a decentralized, electricity-free diagnostics platform using handheld cartridges for nucleic-acid amplification and visual...
ADC manufacturing and linker-payload licensing accelerates next-generation bispecific ADC efforts
Lonza signed a licensing agreement with InduPro to support development of antibody–drug conjugate programs using Lonza’s GlycoConnect and HydraSpace bioconjugation and proprietary linker-payload...
Biotech and clinical testing expansion for kidney transplant rejection risk
Verici Dx said its Tutivia lab-developed kidney transplant rejection risk test received approval from New York State’s Clinical Laboratory Evaluation Program, enabling nationwide availability....
China approval marks first CAR-T for solid tumors
China’s National Medical Products Administration approved Carsgen’s satricabtagene autoleucel (satri-cel, CT-041), positioning it as the first CAR-T therapy globally approved for solid tumors. The...
Sangamo enters bankruptcy after extended gene-editing platform run
Sangamo Therapeutics filed for Chapter 11 bankruptcy and simultaneously agreed to sell major portions of its platform assets, marking a sharp end to the company’s decades-long ZFN-era strategy....
FDA approval expands Trodelvy label
The FDA cleared expanded first-line use of Gilead’s antibody-drug conjugate Trodelvy (sacituzumab govitecan) for triple-negative breast cancer, adding label breadth that puts the drug in direct...